02 Dec Phenotypeca win funding for a feasibility study from the Future Vaccine Manufacturing Research Hub (Vax-Hub), in partnership with The Jenner Institute
Next-generation yeast strain developer and BioCity client company, Phenotypeca Ltd, has been awarded funding from the Future Vaccine Manufacturing Research Hub (Vax-Hub) to conduct a feasibility study that will exploit the genetic diversity of baker’s yeast to optimise virus-like particles (VLPs) for vaccine production. Vax-Hub launched...